Are Options Traders Betting on a Big Move in Regenxbio Stock?
Investors need to pay close attention to RGNX stock based on the movements in the options market lately.
Regenxbio ( RGNX ) Reports Q2 Loss, Lags Revenue Estimates
Regenxbio (RGNX) delivered earnings and revenue surprises of -22.12% and -21.16%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Aligos Therapeutics, Inc. ( ALGS ) Reports Q2 Loss, Misses Revenue Estimates
Aligos Therapeutics (ALGS) delivered earnings and revenue surprises of +34.89% and -3.50%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Clearside Biomedical Announces Plan to Explore Strategic Alternatives to Advance its Proprietary Suprachoroidal Space ( SCS® ) Delivery Platform and Promising Ophthalmology Pipeline
- Proven In-Office, Repeatable, Non-Surgical Procedure for the Targeted Delivery of a Wide Variety of Therapies for Serious Retinal Diseases ...
Clearside Biomedical Announces Plan to Explore Strategic Alternatives to Advance its Proprietary Suprachoroidal Space ( SCS® ) Delivery Platform and Promising Ophthalmology Pipeline - Clearside Biomedical ( NASDAQ:CLSD )
- Proven In-Office, Repeatable, Non-Surgical Procedure for the Targeted Delivery of a Wide Variety of Therapies for Serious Retinal Diseases - - CLS-AX Phase 3-Ready Asset with Global Investigator Support and FDA Alignment on Pivotal Trial Program in wet AMD -
Clearside Biomedical Announces Multiple Presentations to be Featured at the Clinical Trials at the Summit Meeting - Clearside Biomedical ( NASDAQ:CLSD )
- Broad Use of Suprachoroidal Injection Platform Highlighted Across Retinal Indications - - CLS-AX Combines the Flexibility of Anti-VEGF Therapies with the Long-Lasting Benefits of a Tyrosine Kinase Inhibitor - ALPHARETTA, Ga., June 17, 2025 ( GLOBE NEWSWIRE ) -- Clearside Biomedical, Inc.
Clearside Biomedical Announces Multiple Presentations to be Featured at the Clinical Trials at the Summit Meeting
- Broad Use of Suprachoroidal Injection Platform Highlighted Across Retinal Indications ...
Crude Oil Moves Higher; Ciena Posts Downbeat Earnings - Ciena ( NYSE:CIEN ) , ChargePoint Hldgs ( NYSE:CHPT )
U.S. stocks traded mostly lower toward the end of trading, with the Dow Jones falling around 0.1% points on Thursday. The Dow traded down 0.06% to 42,400.42 while the NASDAQ fell 0.40% to 19,381.93. The S&P 500 also fell, dropping, 0.27% to 5,954.96. Communication services shares jumped by 0.4% ...
RegenXBio's Duchenne Drug Is Showing Promise - Regenxbio ( NASDAQ:RGNX )
RGX-202 patients showed 4.5-point NSAA gains from baseline and 6.8 points over natural history at 12 months. RegenXBio targets mid-2026 BLA filing and commercial launch of RGX-202 in 2027. Get the Strategy to Trade Pre-Fed Setups and Post-Fed Swings-Live With Chris Capre on Wednesday, June 11.
Dow Dips Over 100 Points; US Jobless Claims Increase - ChargePoint Hldgs ( NYSE:CHPT ) , Liminatus Pharma ( NASDAQ:LIMN )
U.S. stocks traded lower this morning, with the Dow Jones dipping more than 100 points on Thursday. The Dow traded down 0.33% to 42,287.54 while the NASDAQ fell 0.22% to 19,418.54. The S&P 500 also fell, dropping, 0.25% to 5,955.78. Communication services shares jumped by 0.3% on Thursday.
Coave Therapeutics Establishes New Scientific Advisory Board to Accelerate Innovation in Genetic Medicines for Eye and CNS Diseases
Paris, France - May 21, 2025 - Coave Therapeutics ( 'Coave' ) , a company pioneering the future of genetic medicines, today announces the evolution of its Scientific Advisory Board ( SAB ) .
Regenxbio ( RGNX ) Q1 Earnings and Revenues Lag Estimates
Regenxbio (RGNX) delivered earnings and revenue surprises of -70.73% and 19.07%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Regenxbio ( RGNX ) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Regenxbio (RGNX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Exact Sciences ( EXAS ) Reports Q1 Loss, Tops Revenue Estimates
Exact Sciences (EXAS) delivered earnings and revenue surprises of 43.24% and 2.53%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Chewy, Bausch Health Companies And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Chewy ( NYSE:CHWY ) , Bausch Health Companies ( NYSE:BHC )
U.S. stock futures were lower this morning, with the Dow futures falling around 50 points on Wednesday. Shares of Chewy, Inc. CHWY fell sharply in pre-market trading after the company reported quarterly earnings.
How to Play SRPT Stock After Patient Death Post DMD Therapy Infusion
We advise investors with a long-term horizon to remain invested in Sarepta stock, given its encouraging commercial portfolio and robust pipeline potential.
Regenxbio ( RGNX ) Reports Q4 Loss, Lags Revenue Estimates
Regenxbio (RGNX) delivered earnings and revenue surprises of 20.47% and 7.36%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Will Regenxbio ( RGNX ) Report Negative Earnings Next Week? What You Should Know
Regenxbio (RGNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Castle Biosciences, Inc. ( CSTL ) Reports Next Week: Wall Street Expects Earnings Growth
Castle Biosciences (CSTL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Regenxbio's Gene Therapy Outlook Dims As Rival Treatments Gain Ground, Goldman Sachs Warns - Regenxbio ( NASDAQ:RGNX )
Goldman Sachs downgraded Regenxbio, cutting the price target due to concerns over ABBV-RGX-314's market appeal. Data for ABBV-RGX-314 in wet AMD is expected in 2026, while Phase 3 program for diabetic retinopathy with suprachoroidal delivery is planned
Wall Street Analysts Think Regenxbio ( RGNX ) Could Surge 333.01%: Read This Before Placing a Bet
The consensus price target hints at a 333% upside potential for Regenxbio (RGNX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
AbbVie ( ABBV ) Q4 2024 Earnings Call Transcript
ABBV earnings call for the period ending December 31, 2024.
Macular Degeneration Treatment Market Size is Projected to Reach USD 18.59 Billion by 2033, Growing at a CAGR of 7.06%: Straits Research
New York, United States, Jan. 29, 2025 ( GLOBE NEWSWIRE ) -- The eye's macula is impacted by macular degeneration, a neurodegenerative condition. Macular degeneration will cause loss of central vision because it gives the clear main idea required to see objects.
Wall Street Analysts See a 357.36% Upside in Regenxbio ( RGNX ) : Can the Stock Really Move This High?
The mean of analysts' price targets for Regenxbio (RGNX) points to a 357.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Why KB Home Shares Are Trading Higher By Over 9%; Here Are 20 Stocks Moving Premarket - Aehr Test System ( NASDAQ:AEHR ) , AtlasClear Holdings ( AMEX:ATCH )
Shares of KB Home KBH rose sharply in today's pre-market trading after the company posted better-than-expected fourth-quarter financial results. KB Home reported fourth-quarter revenue of $2 billion, beating analyst estimates of $1.99 billion.
Novartis intrathecal onasemnogene abeparvovec Phase III study meets primary endpoint in children and young adults with SMA
Ad hoc announcement pursuant to Art. 53 LR ...
What's Going On With REGENXBIO Shares Monday? - Regenxbio ( NASDAQ:RGNX )
REGENXBIO Inc. RGNX stock is trading higher on Monday after the company reached a critical point in its trial for Duchenne gene therapy. The Details: The company announced that it has dosed the first patient in its trial for RGX-202, a potential gene therapy designed to treat Duchenne muscular ...
Clearside Biomedical Partner Arctic Vision Executes Commercial Collaboration Agreement with Santen Pharmaceutical Co., Ltd for ARVN001 Suprachoroidal Space Injection Therapy for the Treatment of Uveitic Macular Edema
- Partnership Creates New Opportunities to Address Unmet Needs Related to Posterior Segment Eye Diseases in China ...
Regenxbio ( RGNX ) Reports Q3 Loss, Tops Revenue Estimates
Regenxbio (RGNX) delivered earnings and revenue surprises of -0.86% and 13.34%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Gene Therapy Market Set for 19% CAGR Surge, Reaching USD 38.34 Billion by 2031 | SkyQuest Technology
Westford, USA, Sept. 12, 2024 ( GLOBE NEWSWIRE ) -- SkyQuest projects that the Global Gene Therapy Market will reach a value of USD 38.34 Billion by 2031, with a CAGR of 19% during the forecast period ( 2024-2031 ) .
New Research Reveals Emergence of New Variants of Coronavirus to Boost COVID-19 Therapeutics Market Growth - AbbVie ( NYSE:ABBV ) , BioNTech ( NASDAQ:BNTX )
PALM BEACH, Fla., Sept. 04, 2024 ( GLOBE NEWSWIRE ) -- FN Media Group News Commentary - The SARS-CoV-2, literally affected the whole world in these past years and has increased a global search for therapies and treatments.
Wall Street Analysts Think Regenxbio Could Surge 234.37%: Read This Before Placing a Bet - Regenxbio ( NASDAQ:RGNX )
Shares of Regenxbio RGNX have gained 17.7% over the past four weeks to close the last trading session at $12.51, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication.
Wall Street Analysts Think Regenxbio ( RGNX ) Could Surge 234.37%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 234.4% in Regenxbio (RGNX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Regenxbio ( RGNX ) Reports Q2 Loss, Tops Revenue Estimates
Regenxbio (RGNX) delivered earnings and revenue surprises of 18.60% and 2.59%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Emerging Gene Therapies Signal Transformative Shift in Retinal Disorder Treatment, According to Spherix Global Insights
EXTON, PA., June 20, 2024, July 24, 2024 ( GLOBE NEWSWIRE ) -- The American Society of Retinal Specialists ( ASRS ) annual meeting held last week in Stockholm, Sweden, showcased groundbreaking advancements in gene therapy for retinal disorders.
Regenxbio ( RGNX ) Surges 18.3%: Is This an Indication of Further Gains?
Regenxbio (RGNX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Here's Why Sarepta ( SRPT ) Stock Price Surged 57% YTD
Sarepta (SRPT) surges on the commercial potential of its Elevidys, the first FDA-approved gene therapy for Duchenne muscular dystrophy.
Why Is Clearside Biomedical Stock Gaining Today? - Clearside Biomedical ( NASDAQ:CLSD )
Oppenheimer initiated coverage on Clearside Biomedical Inc CLSD, a biopharmaceutical company focused on delivering therapies to the back of the eye through the suprachoroidal ( SCS ) space.
Regenxbio ( RGNX ) Soars 6.4%: Is Further Upside Left in the Stock?
Regenxbio (RGNX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Ophthalmologists Favor Genentech's Vabysmo and Regeneron's Eylea HD for Diabetic Macular Edema Treatment Despite Payer Constraints
EXTON, PA., June 20, 2024, June 24, 2024 ( GLOBE NEWSWIRE ) -- The treatment landscape for Diabetic Macular Edema ( DME ) continues to evolve, with innovative therapies and emerging data significantly shaping prescribing patterns.
FDA Expands Sarepta's ( SRPT ) DMD Gene Therapy Label
Following the label expansion, Sarepta's (SRPT) Elevidys is approved to treat all DMD patients aged four years and older, regardless of ambulation status.
Sarepta Skyrockets After FDA Signs Off On Duchenne Gene Therapy
Sarepta Stock Skyrockets After FDA Approves Duchenne Gene Therapy Investor's Business Daily ...
REGENXBIO ( NASDAQ:RGNX ) Upgraded to "Hold" at StockNews.com
REGENXBIO ( NASDAQ:RGNX - Get Free Report ) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating in a research report issued on Tuesday. Several other equities research analysts also recently weighed in on the company.
Urogen Pharma Surges 9.7%: Is This an Indication of Further Gains? - UroGen Pharma ( NASDAQ:URGN ) , Regenxbio ( NASDAQ:RGNX )
Urogen Pharma URGN shares soared 9.7% in the last trading session to close at $19.20. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 32.5% gain over the past four weeks.
Urogen Pharma ( URGN ) Surges 9.7%: Is This an Indication of Further Gains?
Urogen Pharma (URGN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
REGENXBIO ( NASDAQ:RGNX ) Lowered to Sell at StockNews.com
StockNews.com lowered shares of REGENXBIO ( NASDAQ:RGNX - Free Report ) from a hold rating to a sell rating in a report issued on Monday.
Goldman Sachs Optimistic About Regenxbio's Gene Therapy Pipeline, Sees Over 160% Upside
Goldman Sachs has initiated coverage on Regenxbio Inc ( NASDAQ:RGNX ) , citing the potential for the company's gene therapy platform. The company's pipeline includes gene therapy candidates for ophthalmology ( wet AMD and diabetic retinopathy ) , Duchenne muscular dystrophy ( DMD ) , and Hunter ...
Goldman Sachs Optimistic About Regenxbio's Gene Therapy Pipeline, Sees Over 160% Upside - Regenxbio ( NASDAQ:RGNX )
Goldman Sachs has initiated coverage on Regenxbio Inc RGNX, citing the potential for the company's gene therapy platform. The company's pipeline includes gene therapy candidates for ophthalmology ( wet AMD and diabetic retinopathy ) , Duchenne muscular dystrophy ( DMD ) , and Hunter syndrome.
Assessing Regenxbio: Insights From 4 Financial Analysts
In the latest quarter, 4 analysts provided ratings for Regenxbio ( NASDAQ:RGNX ) , showcasing a mix of bullish and bearish perspectives. The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the ...
REGENXBIO ( NASDAQ:RGNX ) Upgraded to "Hold" by StockNews.com
StockNews.com upgraded shares of REGENXBIO ( NASDAQ:RGNX - Free Report ) from a sell rating to a hold rating in a report published on Thursday. Several other research firms also recently weighed in on RGNX. Leerink Partnrs upgraded shares of REGENXBIO from a market perform rating to an ...
